Showing 4121-4130 of 9120 results for "".
- GW Prior Certification Coordinator Offers Tips at ElderDermhttps://practicaldermatology.com/news/GW-Prior-Certification-Coordinator-Offers-Tips-ElderDerm/2474666/There are no shortcuts to getting dermatologic treatments authorized by Medicaid and insurance companies, George Washington University Department of Dermatology’s prior certification coordinator said at the ElderDerm 2025 Conference in Washington, DC. Effort and diligence are the keys when
- Arcutis Announces Expert Statements on Genital Psoriasishttps://practicaldermatology.com/news/arcutis-announces-expert-statements-on-genital-psoriasis/2474665/Arcutis Biotherapeutics, Inc. has announced new consensus statements aimed at improving the diagnosis and management of genital psoriasis, according to a company press release. The 14 statements, developed by a multidisciplinary group of dermatology and immunology experts with the Genital
- Dermeleve to Modify Program for Sampleshttps://practicaldermatology.com/news/Dermeleve-Modify-Program-Samples/2474651/Dermeleve will transition away from its auto-ship model and self-serve request program for samples, but will still offer samples directly to patients and to clinicians who choose to hole wholesale inventory, the company said in an email to partners. “To ensure your patients can still ‘try
- Study: Ultralow-Dose Rituximab Effective in Pemphigushttps://practicaldermatology.com/news/study-ultralow-dose-rituximab-effective-in-pemphigus/2474602/A new 52-week clinical trial found that ultralow-dose rituximab (ULRTX) achieved comparable efficacy, safety, and B-cell depletion to standard and low-dose regimens in patients with moderate-to-severe pemphigus vulgaris (PV) and pemphigus foliaceus (PF).
- Study: Nonprescription Balm Performs on Par with Topical Antibiotichttps://practicaldermatology.com/news/study-nonprescription-balm-performs-on-par-with-topical-antibiotic/2474439/A new randomized controlled trial found that a nonprescription repairing balm containing panthenol, madecassoside, and metal salts (CB5) performs equivalently to a topical antibiotic (PSO) for wound healing after cryotherapy of actinic keratoses (AKs).
- Market for Atopic Dermatitis Treatments to Surge Past $22 Billionhttps://practicaldermatology.com/news/market-for-atopic-dermatitis-treatments-to-surge-past-22-billion/2474524/The global atopic dermatitis (AD) market is projected to more than double over the next decade, reaching $22.37 billion by 2034, new research from Polaris Market Research indicates. Driven by an annual growth rate of 8.5%, the
- Simvastatin Shows Promise as Adjunct Treatment for Vitiligo in Meta-Analysishttps://practicaldermatology.com/news/simvastatin-shows-promise-as-adjunct-treatment-for-vitiligo-in-meta-analysis/2474442/A new meta-analysis highlights the therapeutic potential of simvastatin for vitiligo, showing significant benefits in repigmentation and disease severity reduction. Vitiligo, an autoimmune disorder marked by melanocyte destruc
- ARRECTOR: Roflumilast Foam 0.3% Shows Strong Efficacy for Scalp and Body Psoriasishttps://practicaldermatology.com/news/arrector-roflumilast-foam-shows-strong-efficacy-for-scalp-and-body-psoriasis/2474520/A once-daily roflumilast foam formulation significantly improved scalp and body psoriasis in a pivotal phase 3 trial, according to a press release from Arcutis Biotherapeutics, Inc. Researchers for the randomized, double-blin
- Candela Announces GentleMax Pro Integration into Laser Hair Removal Systemhttps://practicaldermatology.com/news/ideal-image-expands-laser-hair-removal-capabilities-with-candelas-gentlemax-pro-plus-and-glx-delivery-system/2474466/Ideal Image has integrated Candela’s latest laser technology—the GentleMax Pro Plus system with the new GLX Delivery System—into select centers across the U.S., according to a Candela news release. The GentleMax Pro Plus syste
- Triple-Combo Gel Reduces Acne Lesions, Scarring, and PIH Over 6 Months: Studyhttps://practicaldermatology.com/news/study-triple-combo-gel-reduces-acne-lesions-scarring-and-pih-over-6-months/2474438/Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) was associated with significant long-term efficacy and safety in the treatment of moderate acne and associated sequelae, results from a new 24-week open-label study indicate.